Cogent Biosciences (NASDAQ:COGT) Rating Reiterated by Needham & Company LLC

Cogent Biosciences (NASDAQ:COGTGet Free Report)‘s stock had its “buy” rating restated by investment analysts at Needham & Company LLC in a note issued to investors on Monday, Benzinga reports. They presently have a $15.00 price objective on the technology company’s stock. Needham & Company LLC’s target price points to a potential upside of 155.10% from the company’s current price.

Several other equities research analysts have also commented on COGT. HC Wainwright reduced their price objective on Cogent Biosciences from $27.00 to $13.00 and set a “buy” rating for the company in a research note on Friday, December 15th. Citigroup assumed coverage on Cogent Biosciences in a research note on Thursday. They issued a “buy” rating and a $11.00 price target for the company. JPMorgan Chase & Co. assumed coverage on Cogent Biosciences in a research note on Friday, December 8th. They issued an “overweight” rating and a $18.00 price target for the company. Finally, Wedbush reiterated a “neutral” rating on shares of Cogent Biosciences in a research note on Tuesday, January 9th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $15.43.

Get Our Latest Stock Report on COGT

Cogent Biosciences Price Performance

NASDAQ:COGT opened at $5.88 on Monday. The firm has a market capitalization of $506.41 million, a price-to-earnings ratio of -2.52 and a beta of 1.39. Cogent Biosciences has a one year low of $3.67 and a one year high of $14.50. The business has a fifty day moving average price of $5.50 and a 200-day moving average price of $8.45.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its position in shares of Cogent Biosciences by 10.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 11,122 shares of the technology company’s stock valued at $129,000 after purchasing an additional 1,018 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Cogent Biosciences by 9.5% during the second quarter. ProShare Advisors LLC now owns 13,558 shares of the technology company’s stock valued at $161,000 after purchasing an additional 1,179 shares in the last quarter. MetLife Investment Management LLC grew its position in shares of Cogent Biosciences by 3.6% during the second quarter. MetLife Investment Management LLC now owns 35,235 shares of the technology company’s stock valued at $417,000 after purchasing an additional 1,217 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Cogent Biosciences by 8.1% during the second quarter. Principal Financial Group Inc. now owns 18,464 shares of the technology company’s stock valued at $219,000 after purchasing an additional 1,379 shares in the last quarter. Finally, Values First Advisors Inc. grew its position in shares of Cogent Biosciences by 12.3% during the second quarter. Values First Advisors Inc. now owns 17,052 shares of the technology company’s stock valued at $202,000 after purchasing an additional 1,866 shares in the last quarter.

About Cogent Biosciences

(Get Free Report)

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.

Further Reading

Analyst Recommendations for Cogent Biosciences (NASDAQ:COGT)

Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.